Pfizer optimistic about rebound in drug sales, raises 2020 profit forecast

The Pfizer logo is seen at their world headquarters in New York
Pfizer Inc raised its full-year earnings forecast on Tuesday, as the US drugmaker predicted a recovery in vaccination rates and visits to doctors after patients avoided hospitals due to the coronavirus crisis in the first half.

The report comes at the start of a busy week of US pharmaceutical earnings, with investors focusing on updates on the development of vaccines and treatments for the pandemic.

Pfizer and German partner BioNTech SE said on Monday they were beginning a late-stage, global study to test their coronavirus vaccine candidate, launching on the same day as a trial for a rival candidate developed by Moderna Inc .

Pfizer's shares rose nearly 2 per cent to $38.26 in morning trading after the company also beat second-quarter earnings estimates.

In the quarter, the company took a roughly $500 million hit to sales due to a drop in visits to hospital or the doctor's office globally due to the health crisis.

The impact, however, was cushioned by demand for blood thinner Eliquis, which has been used by some doctors to help treat Covid-19, and cancer drug Ibrance.

Pfizer raised its forecast for 2020 adjusted profit to between $2.28 and $2.38 per share, from a prior estimate of between $2.25 and $2.35, adding that it expected doctor's visits to start recovering in the third quarter.

The drugmaker said its 2020 forecast did not include any revenue from its experimental coronavirus vaccine.

The company also was able to restart studies of drugs in development in late April after an initial disruption due to the global outbreak.

In the second quarter, sales of several important treatments beat consensus estimates, which would help soothe investors who had modest expectations going into earnings, said Cantor Fitzgerald analyst Louise Chen.

Excluding items, Pfizer earned 78 cents per share, beating estimate of 66 cents, according to IBES data from Refinitiv.

Sales of $11.80 billion also topped estimates of $11.55 billion.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel